NASDAQ:GLUE

Monte Rosa Therapeutics - GLUE Stock Forecast, Price & News

$6.94

-0.28 (-3.88%)

(As of 03/20/2023 12:00 AM ET)

Add

Compare

Today's Range: $6.86
▼
$7.42
50-Day Range: $5.95
▼
$8.21
52-Week Range: $5.74
▼
$15.52

Volume: 78,225 shs
Average Volume: 143,419 shs
Market Capitalization: $335.89 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.40

Institutional Ownership

Monte Rosa Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 165.1% Upside
$18.40 Price Target
Short Interest: Bearish
5.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.50
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.82) to ($2.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

539th out of 988 stocks

Biological Products, Except Diagnostic Industry

97th out of 162 stocks

3.4

Analyst's Opinion

Consensus Rating
Monte Rosa Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.40, Monte Rosa Therapeutics has a forecasted upside of 165.1% from its current price of $6.94.
Amount of Analyst Coverage
Monte Rosa Therapeutics has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.90% of the float of Monte Rosa Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Monte Rosa Therapeutics has a short interest ratio ("days to cover") of 15.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Monte Rosa Therapeutics has recently decreased by 8.03%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Monte Rosa Therapeutics does not currently pay a dividend.
Dividend Growth
Monte Rosa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GLUE.

2.5

News and Social Media Coverage

News Sentiment
Monte Rosa Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Monte Rosa Therapeutics this week, compared to 0 articles on an average week.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Monte Rosa Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Monte Rosa Therapeutics is held by insiders.
Percentage Held by Institutions
83.19% of the stock of Monte Rosa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Monte Rosa Therapeutics are expected to grow in the coming year, from ($2.82) to ($2.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Monte Rosa Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Monte Rosa Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Monte Rosa Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Stock News Headlines

March 16, 2023 | finanznachrichten.de

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

March 16, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Morphosys Ag (MOR), Monte Rosa Therapeutics (GLUE)

March 21, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

March 16, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

February 28, 2023 | seekingalpha.com

GLUE Monte Rosa Therapeutics, Inc.

February 6, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

February 6, 2023 | finance.yahoo.com

Here's Why We're Not Too Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation

February 3, 2023 | finance.yahoo.com

Monte Rosa Therapeutics to Present at Upcoming Investor Conferences

March 21, 2023 | Investing Daily (Ad)

27 U.S. Cities Where Stocks Yield 26% a Year

What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.

January 25, 2023 | finance.yahoo.com

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

January 9, 2023 | finance.yahoo.com

Monte Rosa Therapeutics Outlines Progress Across Portfolio of Molecular Glue Degraders and Key Anticipated Milestones for 2023

November 17, 2022 | finance.yahoo.com

Alphabet Inc (GOOGL) Investment Portfolio: Top 15 Companies

November 10, 2022 | finanznachrichten.de

Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

November 10, 2022 | finance.yahoo.com

Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates

November 1, 2022 | finance.yahoo.com

Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors

October 20, 2022 | finance.yahoo.com

Monte Rosa Therapeutics to Present at 5th Annual Targeted Protein Degradation Summit and 34th EORTC-NCI-AACR Symposium

September 19, 2022 | nasdaq.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

August 30, 2022 | finance.yahoo.com

We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate

August 11, 2022 | apnews.com

Monte Rosa Therapeutics: Q2 Earnings Snapshot

July 17, 2022 | uk.finance.yahoo.com

Monte Rosa Therapeutics, Inc. (GLUE)

June 14, 2022 | finance.yahoo.com

Upcoming 220K-square-foot South End lab project almost fully leased

May 17, 2022 | nasdaq.com

Monte Rosa Therapeutics vs. Binance Coin: Price Relationship Crosses Threshold

April 15, 2022 | seekingalpha.com

Monte Rosa Therapeutics (GLUE) Investor Presentation - Slideshow

April 8, 2022 | tmcnet.com

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential

April 8, 2022 | finance.yahoo.com

Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022

March 29, 2022 | seekingalpha.com

Monte Rosa Therapeutics GAAP EPS of -$2.96 misses by $0.43

March 29, 2022 | finance.yahoo.com

Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GLUE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monte Rosa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GLUE Company Calendar

Last Earnings: 3/29/2022
Today: 3/20/2023
Next Earnings (Estimated): 5/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLUE
CUSIP: N/A
CIK: 1826457
Web: www.monterosatx.com
Phone: 617-949-2643
Fax: N/A
Employees: 93
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.40
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $11.00
Forecasted Upside/Downside: +165.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.29)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-73,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.42%
Return on Assets: -30.46%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.55
Quick Ratio: 13.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.47 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 48,399,000
Free Float: 46,705,000
Market Cap: $335.89 million
Optionable: Not Optionable
Beta: 0.96

Key Executives

Dr. Markus Warmuth M.D. (Age 51)
Pres, CEO & Director
Comp: $842.99k

Dr. Owen B. Wallace Ph.D. (Age 53)
Chief Scientific Officer
Comp: $578.36k

Dr. Filip Janku M.D. (Age 47)
Ph.D., Chief Medical Officer
Comp: $511.55k

Mr. Ajim A. Tamboli C.F.A. (Age 45)
Chief Financial Officer

Ms. Jennifer Champoux
Sr. VP of Operations

Dr. Sharon Townson Ph.D. (Age 47)
Chief Technology Officer

Mr. Phil Nickson J.D. (Age 43)
Ph.D., Gen. Counsel

Dr. John C. Castle Ph.D. (Age 51)
Chief Data Scientist

Dr. Jullian G. Jones J.D. (Age 46)
M.B.A., Ph.D., Chief Bus. Officer

Dr. Silvia Buonamici Ph.D.
Sr. VP of Drug Discovery Biology

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

GLUE Stock - Frequently Asked Questions

Should I buy or sell Monte Rosa Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monte Rosa Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GLUE shares.
View GLUE analyst ratings or view top-rated stocks.
What is Monte Rosa Therapeutics' stock price forecast for 2023?: 4 equities research analysts have issued twelve-month price targets for Monte Rosa Therapeutics' stock. Their GLUE share price forecasts range from $11.00 to $22.00. On average, they predict the company's stock price to reach $18.40 in the next twelve months. This suggests a possible upside of 165.1% from the stock's current price.
View analysts price targets for GLUE or view top-rated stocks among Wall Street analysts.
How have GLUE shares performed in 2023?: Monte Rosa Therapeutics' stock was trading at $7.61 at the beginning of the year. Since then, GLUE stock has decreased by 8.8% and is now trading at $6.94.
View the best growth stocks for 2023 here.
Are investors shorting Monte Rosa Therapeutics?: Monte Rosa Therapeutics saw a drop in short interest in February. As of February 28th, there was short interest totaling 2,290,000 shares, a drop of 8.0% from the February 13th total of 2,490,000 shares. Based on an average daily volume of 145,000 shares, the days-to-cover ratio is presently 15.8 days. Currently, 5.9% of the company's stock are short sold.
View Monte Rosa Therapeutics' Short Interest.
When is Monte Rosa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our GLUE earnings forecast.
How were Monte Rosa Therapeutics' earnings last quarter?: Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) issued its quarterly earnings results on Tuesday, March, 29th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.43.

What ETFs hold Monte Rosa Therapeutics' stock?: ETFs with the largest weight of Monte Rosa Therapeutics (NASDAQ:GLUE) stock in their portfolio include BlackRock Future Health ETF (BMED).Fidelity Growth Opportunities ETF (FGRO).
When did Monte Rosa Therapeutics IPO?: (GLUE) raised $211 million in an initial public offering (IPO) on Thursday, June 24th 2021. The company issued 11,700,000 shares at a price of $17.00-$19.00 per share.
What is Monte Rosa Therapeutics' stock symbol?: Monte Rosa Therapeutics trades on the NASDAQ under the ticker symbol "GLUE."
Who are Monte Rosa Therapeutics' major shareholders?: Monte Rosa Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include NEA Management Company LLC (15.89%), Avoro Capital Advisors LLC (8.94%), Price T Rowe Associates Inc. MD (7.61%), T. Rowe Price Investment Management Inc. (4.00%), Geode Capital Management LLC (1.16%) and Millennium Management LLC (0.81%). Insiders that own company stock include Cormorant Asset Management, Lp and Versant Venture Capital Vi, L.
How do I buy shares of Monte Rosa Therapeutics?: Shares of GLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Monte Rosa Therapeutics' stock price today?: One share of GLUE stock can currently be purchased for approximately $6.94.
How much money does Monte Rosa Therapeutics make?: Monte Rosa Therapeutics (NASDAQ:GLUE) has a market capitalization of $335.89 million. The company earns $-73,960,000.00 in net income (profit) each year or ($2.29) on an earnings per share basis.
How can I contact Monte Rosa Therapeutics?: The official website for the company is www.monterosatx.com. The company can be reached via phone at 617-949-2643 or via email at ir@monterosatx.com.

This page (NASDAQ:GLUE) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Monte Rosa Therapeutics - GLUE Stock Forecast, Price & News

Monte Rosa Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Monte Rosa Therapeutics (NASDAQ:GLUE) Stock

GLUE Stock News Headlines

GLUE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

GLUE Stock - Frequently Asked Questions

Overall MarketRank^™